On Thursday, drugmaker Sanofi announced that it is joining Eli Lily and Novo Nordisk in reducing the price of insulin. The three companies, which dominate the global insulin market, were recently sued by the state of California, alleging they illegally drive up the cost of the drug.

"It seemed like only a matter of time before Sanofi also made changes," said Stacie Dusetzina, a health policy professor at Vanderbilt University Medical Center. "You don't want to be a standout."

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events
  • Access to other award-winning ALM websites including and

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.